Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2021-02-18 Director's Dealing
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice 4 pages 195.1KB
Director's Dealing Classification · 100% confidence The document is titled 'CHANGE OF DIRECTOR’S INTEREST NOTICE' and references 'Appendix 3Y – Change of Director’s Interest Notice' which is a standard form used in Australian Securities Exchange (ASX) filings to report changes in directors' shareholdings. The content details the director's name, date of last notice, nature of interest, number of securities held before and after the change, and transaction details such as on-market purchase. There is no financial performance data, earnings information, or management discussion. The document is a regulatory announcement about a director's personal share transactions. Therefore, it fits the category of Director's Dealing (DIRS). The document length and detail support this classification with high confidence.
2021-02-18 English
PYC to Participate in RNA Discussion - CEO BIO Conference 2 pages 198.2KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that PYC Therapeutics' incoming CEO will participate in a panel at the 2021 BIO CEO & Investor Digital Conference. It contains no financial data, no regulatory filing references, no report attachments, and no detailed financial or management information. It is an announcement related to investor relations and company events rather than a formal financial or regulatory filing. Therefore, it best fits the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2021-02-10 English
Quarterly Activities Report and Appendix 4C 8 pages 414.4KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated January 29, 2021, titled 'Quarterly Activities Report' and includes detailed highlights and updates on the company's activities during the fourth quarter of 2020. It discusses operational progress, pipeline developments, management appointments, and a capital raise. Importantly, it includes an Appendix 4C Quarterly cash flow report, which is a regulatory requirement for entities listed on the ASX to report quarterly cash flows and financing activities. The document contains actual financial data such as cash flows from operating, investing, and financing activities, and reconciliations of cash and cash equivalents. The presence of substantive financial data and the quarterly period covered (Q4 2020) indicate this is a comprehensive interim/quarterly report rather than a brief announcement or a simple regulatory filing. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q4 2020
2021-01-28 English
ICR Conference Presentation 18 pages 1.5MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from PYC Therapeutics Limited dated January 2021, providing an update on the company's business, technology, drug development pipeline, leadership, and financial information. It is structured as a slide deck with extensive information on the company's RNA therapeutics platform, drug candidates, market potential, and strategic plans. The content is typical of an investor presentation aimed at providing comprehensive insights into the company's operations, strategy, and outlook. There is no indication that this is an official annual report, earnings release, regulatory filing, or other formal report type. The document explicitly states it is a presentation aid and includes forward-looking statements and disclaimers typical of investor presentations. Therefore, the most appropriate classification is Investor Presentation (IP).
2021-01-13 English
PYC to Present at ICR Westwicke Conference 2 pages 140.2KB
Investor Presentation Classification · 90% confidence The document is an ASX announcement dated January 6, 2021, about PYC Therapeutics' participation and presentation at the ICR Westwicke Conference. It includes details about the event date, webcast link, and company background. There are no financial statements, earnings data, or detailed report content. The document is a notification of an upcoming investor presentation event rather than the presentation itself or a financial report. The length is 3667 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best as an Investor Presentation announcement (IP).
2021-01-05 English
Visual Evidence of Lead Drugs Efficacy 4 pages 314.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 16 December 2020 from PYC Therapeutics Limited. It discusses preclinical efficacy results of their lead drug candidate VP-001 in patient-derived models for Retinitis Pigmentosa type 11. The content focuses on scientific and clinical development updates, including experimental results and future milestones such as toxicity assessments. There are no financial statements, regulatory certifications, voting results, or management changes. The document is a corporate announcement about drug development progress rather than a financial report, regulatory filing, or meeting material. It is not a full annual or interim report, nor an earnings release. Given the nature of the content and the fact it is an ASX announcement, the best fitting category is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory announcements that do not fit other specific categories. The document length (7203 characters) and detailed scientific content support this classification with high confidence.
2020-12-15 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.